Simmitecan

盐酸希明替康

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameSimmitecan
Drug Alias NameSimmitecan HydrochlorideLP
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsSolid tumoursColorectal NeoplasmsCarcinoma, Neuroendocrine +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShangHai HaiHe Biopharma Co LtdShanghai Institute Of Materia Medica, Chinese Academy Of Sciences
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesPeking University
Inactive CompaniesHaihe Biopharma (HK) LtdShanghai Institute Of Materia Medica, Chinese Academy Of SciencesShangHai HaiHe Biopharma Co Ltd
Active IndicationsNeuroendocrine Tumors
Inactive IndicationsSolid tumoursColorectal NeoplasmsCarcinoma, Neuroendocrine

Other Information

ATC CodeN/A
Related LinksN/A